Veradermics completes $294.8 million IPO with full underwriter option exercise

Veradermics (NYSE: MANE) completed its initial public offering, raising approximately $294.8 million in gross proceeds before fees and expenses, according to a company statement.

The dermatology-focused biopharmaceutical company sold 17,339,294 shares at $17.00 per share, including 2,261,647 shares from the full exercise of underwriters' option to purchase additional shares. The company's shares began trading on the New York Stock Exchange on February 4, 2026.

Jefferies, Leerink Partners, Citigroup, and Cantor served as joint book-running managers for the offering. All shares in the offering were sold by the company.

Based in New Haven, Connecticut, Veradermics describes itself as a late clinical-stage biopharmaceutical company developing treatments for aesthetic and dermatological conditions. The company's lead program, VDPHL01, is an oral, extended-release formulation of minoxidil being developed as a treatment for pattern hair loss in men and women.

The registration statements for the offering were filed with the Securities and Exchange Commission and are effective. The offering was conducted through a prospectus available from the underwriters.

You May Also Be Interested In

• MoonLake prices $200 million public offering at $20 per share
• Definium Therapeutics prices $700M public offering at $34 per share
• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share